ArticleFrontiers in endocrinology2026
Two-cohort machine learning approach for predicting the risk of secondary hyperlipidemia in patients with depression.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secondary hyperlipidemia is a common and serious complication in patients with clinically diagnosed depressive disorders, yet early screening tools are lacking. This study aims to develop and validate a machine learning-based model to predict the risk of secondary hyperlipidemia in this population. Methods: We conduct a retrospective study of 627 patients (mean age: 44.5 ± 13.5 years; 51.9% female). LASSO regression was utilized for feature selection, followed by the development of seven predictive models is used. Model performance is evaluated using the Area Under the Curve (AUC), calibration curves, and Decision Curve Analysis (DCA). The SHapley Additive exPlanations (SHAP) method provides individual-level interpretation. Results: Six core predictors are identified: Body Mass Index (BMI), weekly physical activity, long-term medication, emotion regulation disorder, C-reactive protein (CRP), and Fasting Plasma Glucose (FPG). Among the evaluated models, the Decision Tree model demonstrates the most clinically appropriate and generalizable performance, with an AUC of 0.87 (95% CI: 0.82-0.92) in external validation. Conclusion: The integration of machine learning with routine clinical data provides a highly accurate and interpretable tool for the early identification of secondary hyperlipidemia in patients with depression. This approach may facilitate personalized preventive interventions and improve long-term metabolic health outcomes in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.